Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01525875
Recruitment Status : Completed
First Posted : February 3, 2012
Last Update Posted : January 20, 2016
Information provided by (Responsible Party):
Mark Lebwohl, Icahn School of Medicine at Mount Sinai

February 1, 2012
February 3, 2012
January 20, 2016
August 2012
March 2015   (Final data collection date for primary outcome measure)
Reversal of elastic fiber calcification [ Time Frame: Baseline, Month 12, and Month 24 ]
A blinded dermatopathologist will grade skin biopsies on the density of Von Kossa staining. We will assess changes in the amount of calcification of elastic fibers by assessing von Kossa staining per unit area of dermis
Same as current
Complete list of historical versions of study NCT01525875 on Archive Site
  • Reversal of clinical skin lesions [ Time Frame: Screening, Months 6, 12, 18 and 24 ]
    Changes in skin skin lesions observed through investigator evaluations and clinical photographs
  • Rate of disease progression [ Time Frame: Baseline, Month 12 and Month 24 ]
    Changes observed through ophthalmologic examinations
  • Rate of disease progression [ Time Frame: Month 12 ]
    Observed through ophthalmologic examinations
  • Rate of disease progression [ Time Frame: Month 24 ]
    Observed through ophthalmologic examinations
Same as current
Not Provided
Not Provided
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
The purpose of this study is to evaluate the effectiveness of magnesium oxide supplements on the reversal of calcium deposits in the skin, and the yellow bumps and folds of skin in subjects with pseudoxanthoma elasticum (PXE). Magnesium oxide is a dietary supplement that has been shown in some research to reduce these calcium deposits. This study consists of two parts. The first part is a year-long, double-blind, placebo-controlled study. Part two is an open-label, year-long study. In Part 1, qualified subjects will be randomized to receive either magnesium oxide supplements or placebo, in a 1:1 ratio for the first 12 months. The starting dose will be 1000 mg daily, and depending on tolerability, doses may be decreased. Baseline evaluations will be comprised of: blood tests; clinical evaluations; skin biopsy; eye examination; bone density test; and photography of skin lesions. Subjects will be evaluated at week 2, week 6, month 3, and then every 3 months during the first year. Upon completion of the first year, barring any safety concerns, all subjects will be administered magnesium oxide supplements for up to one additional year. Subjects will undergo the same evaluations/ procedures every 3 months. We hypothesize that the magnesium oxide will cause a reduction in calcifications in the subject's soft tissue/skin. Funding Source - FDA OOPD.

Pseudoxanthoma elasticum (PXE) is a systemic connective tissue disorder involving elastic fiber calcification and fragmentation with major clinical manifestations occurring in the cutaneous, ocular and cardiovascular systems.

Calcification of the elastic fibers leads to cracks in Bruch's membrane, an elastic tissue-containing membrane that separates the vascular choroid from the retinal pigment epithelium. These are known as angioid streaks and may be the only sign of the disease for years. Retinal hemorrhage and loss of vision are common. Calcification of the internal elastic lamina of arteries results in gastrointestinal bleeding, sometimes fatal in nature. Accelerated heart disease is an additional complication.

Cutaneous manifestations are characterized by the presence of yellow papules in a cobblestone pattern or plaques resembling "plucked chicken-skin" in flexural regions. Redundant folds of skin may develop in more advanced cases. The most frequent sites of cutaneous involvement include the neck, axillae, inguinal region, antecubital and popliteal fossae and the periumbilical area. Skin lesions provide an easy way of grading degree of calcification of elastic tissue.

A clinical study of 80 subjects with a variety of cutaneous soft tissue mineralization disorders had the affected areas injected locally with magnesium sulfate while also receiving oral magnesium lactate for 4 to 6 months. About 75% of these subjects showed a significant decrease or complete disappearance of calcification.

More recently, a knockout mouse model for PXE has linked a reversal in calcification to a diet high in magnesium. Mice were placed on diets that were either high or low in phosphate, high or low in magnesium, or on a controlled diet. The mice placed on the high magnesium diet did not show any evidence of connective tissue mineralization, while those on the other diets did show mineralization as characterized by calcification of the connective tissue capsule surrounding the vibrissae.

Based on this information and the research linking increased magnesium levels to decreased calcification, we plan to supplement the diets of PXE patients with magnesium oxide in order to show a reduction in elastic fiber calcification in the skin and to slow the progression of the disease.

Randomized subjects will be instructed to take study drug (active or placebo) for 12 months, then all subjects will receive active study drug for the following 12 months.

When ingested through foods, magnesium has not demonstrated any adverse effects. When obtained through supplements, however, excessive magnesium intake has been known to result in diarrhea as well as other gastrointestinal effects such as nausea, and abdominal cramping. Large pharmacological doses of magnesium have been associated with more serious side effects, such as metabolic alkalosis and hypokalemia with the repeated daily ingestion of 30g of magnesium oxide. Hypermagnesemia may result with excessive magnesium supplement ingestion, however, it has rarely been reported in individuals with normal renal function.

Study data will be analyzed using the Wilcoxon Rank Sum Test to compare changes in physician global assessment of skin lesions, evaluation of target lesions and assessment of biopsies between treatment and placebo groups. Assuming a negligible placebo response, we believe power analyses can be performed on our primary measure in 40 completed subjects as proposed in this study. Analyses will be based on intent-to-treat, with the last observation carried forward. Patients who withdraw for safety, lack of efficacy, and generally those without other documentation will in the absence of the requested 'final-visit evaluation' be assigned the highest (worst) score. A finding of significance based on the intent-to-treat analysis would be supplemented with an analysis of patients completing the trial without any protocol deviations.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Pseudoxanthoma Elasticum
  • Drug: Magnesium Oxide

    Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).

    Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening).

  • Drug: Placebo
    1000 mg (one 500 mg capsule two times daily) of placebo.
  • Active Comparator: Magnesium oxide

    Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).

    Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening).

    Intervention: Drug: Magnesium Oxide
  • Placebo Comparator: Placebo
    Part 1: 1000 mg (one 500 mg capsule two times daily) of placebo.
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
March 2015
March 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subject at least 18 years of age
  • If female, the subject is not pregnant or nursing
  • If female of child bearing potential, the subject has a negative urine pregnancy test at the first visit, and agrees to use an approved method of contraception (hormonal contraceptives [birth control pills, implants [Norplant] or injections [DepoProvera]); intrauterine device (IUD); two forms of barrier methods [condoms and diaphragm]; or abstinence (no sexual activity) throughout the entire study
  • Biopsy confirmed diagnosis of pseudoxanthoma elasticum (documenting some calcification of elastic fibers)
  • Subject has a clinical disease severity grade of at least "1" (Poorly defined, barely visible macules) at screening.
  • Normal kidney function tests

Exclusion Criteria:

  • Any subject who is pregnant or becomes pregnant during the study
  • Subjects with a serum creatinine greater than 1.6 mg/dL
  • Subjects with hypermagnesemia, hypokalemia, or idiopathic hypercalciuria
  • Subjects with kidney disease or renal tubular defects (eg. Fanconi's syndrome), or on dialysis
  • Subjects with hypothyroidism or hypoparathyroidism or primary hyperparathyroidism
  • Subjects with acute gout
  • Subjects with malabsorption, or osteomalacia
  • Subjects on diuretics, magnesium containing antacids, or anabolic steroids
  • Subjects with Cushing's syndrome
  • Subjects receiving lithium and those with significant psychiatric disorders that would likely interfere with participation in this study
  • Subjects taking anti-seizures medications and anti-arrhythmics medications
  • Subjects on tetracycline or metronidazole and ace inhibitors
  • Subjects taking cyclosporine or calcineurin inhibitors
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
GCO 09-1157
Funding Source - FDA OOPD
Not Provided
Not Provided
Mark Lebwohl, Icahn School of Medicine at Mount Sinai
Mark Lebwohl
Not Provided
Principal Investigator: Mark Lebwohl, MD Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP